Zhejiang Tailin Bioengineering Co

Zhejiang Tailin Bioengineering Co EBIT per Share

The EBIT per Share of Zhejiang Tailin Bioengineering Co (300813.SZ) as of Oct 29, 2026 is 0.01 CNY. In the previous year, EBIT per Share was 0.18 CNY — a change of -96.21% (lower).

EBIT per Share

0.01CNY

YoY

-96.21%

Last updated:

EBIT per Share of Zhejiang Tailin Bioengineering Co is 2025 0.01 CNY. EBIT per Share of Zhejiang Tailin Bioengineering Co was 2024 0.18 CNY. It decreases by -96.21% lower compared to the previous year.

The Zhejiang Tailin Bioengineering Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
0.68 CNY
Jan 1, 2019
0.47 CNY
Jan 1, 2020
0.47 CNY
Jan 1, 2021
0.62 CNY
Jan 1, 2022
0.70 CNY
Jan 1, 2023
0.19 CNY
Jan 1, 2024
0.18 CNY
Jan 1, 2025
0.01 CNY
The Zhejiang Tailin Bioengineering Co EBIT per Share history
YEAREBIT per ShareYoY
0.01CNY-96.21%
0.18CNY-0.91%
0.19CNY-73.48%
0.70CNY+12.51%
0.62CNY+31.56%
0.47CNY+1.24%
0.47CNY-30.90%
0.68CNY+2.28%
0.66CNY-2.71%
0.68CNY+227.68%
0.21CNY-50.28%
0.42CNY+128.67%
0.18CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zhejiang Tailin Bioengineering Co Stock analysis

What does Zhejiang Tailin Bioengineering Co do? Zhejiang Tailin Bioengineering Co., Ltd. generates revenue through the research, development, manufacturing, and sales of pharmaceutical equipment, including microbial detection and control technology system products and organic substance analysis instruments. The company's main products consist of consumables, instruments, and equipment used in sterile drug production and quality control, targeting pharmaceutical manufacturers and laboratories. These products serve applications in medical and health, food safety, disease prevention, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection sectors. The firm distributes its products domestically and internationally, with a focus on the Chinese market and overseas markets. The company's revenue streams are derived from the sale of microbial detection and control technology system products, organic substance analysis instruments, and related consumables. Pharmaceutical manufacturers and laboratory facilities are the primary customers purchasing these products for quality assurance and production processes. The application segments include medical and health, food safety, disease prevention, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection, which are served through both domestic and international distribution channels. Zhejiang Tailin Bioengineering's business model centers on selling specialized pharmaceutical equipment to industries requiring sterile drug production and quality control. The firm's products are utilized across multiple sectors such as medical and health, food safety, disease prevention, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection. Sales occur within the domestic market and overseas markets, with a strong emphasis on the Chinese market and international expansion. Zhejiang Tailin Bioengineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zhejiang Tailin Bioengineering Co stock

EBIT per Share of Zhejiang Tailin Bioengineering Co is 0.01 CNY in 2025.

EBIT per Share of Zhejiang Tailin Bioengineering Co changed from 0.18 CNY to 0.01 CNY, representing a -96.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Zhejiang Tailin Bioengineering Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Zhejiang Tailin Bioengineering Co

All Key Metrics — Zhejiang Tailin Bioengineering Co